Becton Dickinson Beats Q1 Estimates on Interventional Tech Growth

Becton Dickinson (BD) delivered a stronger-than-expected start to its fiscal year, posting first-quarter earnings and revenue that surpassed Wall Street projections. Driven by robust demand in its interventional and connected care units, the medical technology giant reported significant bottom-line growth even as it prepares for a major structural separation of its biosciences and diagnostics divisions.

February 9, 2026, 03:57 PM 0 0

For the quarter, the company recorded net income of $382 million, or $1.34 per share, marking a substantial increase from the $303 million reported during the same period last year. On an adjusted basis, earnings reached $2.91 per share, outperforming the $2.81 consensus estimate from analysts polled by FactSet. Total revenue climbed 1.6% to $5.25 billion, also coming in ahead of the $5.15 billion anticipated by the market.

Segment Performance and Strategic Shifts

Growth during the period was largely fueled by the company’s interventional segment, which saw a 5.8% revenue increase, alongside a 5.5% rise in its connected care business. These gains highlight the company's successful pivot toward specialized medical technologies and digital healthcare solutions, which helped offset broader macroeconomic pressures.

Looking ahead to fiscal 2026, Becton Dickinson issued guidance for low-single-digit currency-neutral revenue growth. The company expects adjusted earnings to land between $12.35 and $12.65 per share. This outlook reflects the impending separation of its biosciences and diagnostic solutions business, a strategic move expected to close this Monday, according to the company's financial report.

When reusing this material a link to Money Talk is required.